Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma

NCT06680115 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma (NPC)

Interventions

DRUG: Sintilimab

Sponsor

First Affiliated Hospital of Guangxi Medical University